Generix
Generix SA develops SaaS solutions for supply chain ecosystems. The last earnings update was 148 days ago. More info.
Add to Portfolio Compare Print
- Generix has significant price volatility in the past 3 months.
GENX Share Price and Events
7 Day Returns
1 Year Returns
GENX Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Generix (GENX) | 1.3% | 12.8% | 31.6% | 45.4% | 64.7% | 91.6% |
| FR Software | 1.6% | 5.3% | 22.1% | 21.7% | 89.4% | 173.4% |
| FR Market | 1% | 6% | 15% | 3.5% | 30% | 32.9% |
1 Year Return vs Industry and Market
- GENX outperformed the Software industry which returned 21.7% over the past year.
- GENX outperformed the Market in France which returned 3.5% over the past year.
GENX Value
Is Generix undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Generix
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Generix.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 1 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 8.6% |
| Perpetual Growth Rate | 10-Year FR Government Bond Rate | 0.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year FR Govt Bond Rate | 0.7% |
| Equity Risk Premium | S&P Global | 6.7% |
| Software Unlevered Beta | Simply Wall St/ S&P Global | 1.14 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.137 (1 + (1- 33%) (18.71%)) |
1.187 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.19 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.73% + (1.187 * 6.65%) |
8.63% |
Discounted Cash Flow Calculation for ENXTPA:GENX using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Generix is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (EUR, Millions) | Source |
Present Value Discounted (@ 8.63%) |
|
|---|---|---|---|
| 2019 | 1.80 | Analyst x1 | 1.66 |
| 2020 | 6.20 | Analyst x1 | 5.25 |
| 2021 | 7.80 | Est @ 25.81% | 6.09 |
| 2022 | 9.23 | Est @ 18.29% | 6.63 |
| 2023 | 10.43 | Est @ 13.02% | 6.89 |
| 2024 | 11.40 | Est @ 9.34% | 6.94 |
| 2025 | 12.17 | Est @ 6.76% | 6.82 |
| 2026 | 12.78 | Est @ 4.95% | 6.59 |
| 2027 | 13.25 | Est @ 3.68% | 6.29 |
| 2028 | 13.62 | Est @ 2.8% | 5.95 |
| Present value of next 10 years cash flows | €59.11 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= €13.62 × (1 + 0.73%) ÷ (8.63% – 0.73%) |
€173.73 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= €173.73 ÷ (1 + 8.63%)10 |
€75.94 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= €59.11 + €75.94 |
€135.05 |
| Equity Value per Share (EUR) |
= Total value / Shares Outstanding
= €135.05 / 22.13 |
€6.1 |
| Calculation | Result | |
|---|---|---|
| Value per share (EUR) | From above. | €6.10 |
| Current discount | Discount to share price of
€4.58
= -1 x (€4.58 - €6.10) / €6.10 |
25% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Generix's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Generix's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Generix's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Generix's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-09-30) in EUR | €0.02 |
| ENXTPA:GENX Share Price ** | ENXTPA (2019-04-24) in EUR | €4.58 |
| France Software Industry PE Ratio | Median Figure of 23 Publicly-Listed Software Companies | 25.1x |
| France Market PE Ratio | Median Figure of 416 Publicly-Listed Companies | 16.24x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Generix.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ENXTPA:GENX Share Price ÷ EPS (both in EUR) = 4.58 ÷ 0.02 |
203.18x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Generix is overvalued based on earnings compared to the FR Software industry average.
- Generix is overvalued based on earnings compared to the France market.
Price based on expected Growth
Does
Generix's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 203.18x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts |
116.6%per year |
| France Software Industry PEG Ratio | Median Figure of 16 Publicly-Listed Software Companies | 2.63x |
| France Market PEG Ratio | Median Figure of 273 Publicly-Listed Companies | 1.53x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 203.18x ÷ 116.6% |
1.74x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Generix is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
Generix's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-09-30) in EUR | €1.61 |
| ENXTPA:GENX Share Price * | ENXTPA (2019-04-24) in EUR | €4.58 |
| France Software Industry PB Ratio | Median Figure of 31 Publicly-Listed Software Companies | 1.99x |
| France Market PB Ratio | Median Figure of 617 Publicly-Listed Companies | 1.49x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ENXTPA:GENX Share Price ÷ Book Value per Share (both in EUR) = 4.58 ÷ 1.61 |
2.84x |
* Primary Listing of Generix.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Generix is overvalued based on assets compared to the FR Software industry average.
Value checks
We assess Generix's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Software industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Software industry average (and greater than 0)? (1 check) Generix has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
GENX Future Performance
How is Generix expected to perform in the next 1 to 3 years based on estimates from 1 analyst?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Generix's earnings growth is expected to exceed the low risk savings rate of 0.7%.
Growth vs Market Checks
- Generix's earnings growth is expected to exceed the France market average.
- Generix's revenue growth is expected to exceed the France market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| ENXTPA:GENX Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts | 116.6% |
| ENXTPA:GENX Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts | 7.7% |
| France Software Industry Earnings Growth Rate | Market Cap Weighted Average | 15.6% |
| France Software Industry Revenue Growth Rate | Market Cap Weighted Average | 9.1% |
| France Market Earnings Growth Rate | Market Cap Weighted Average | 13.4% |
| France Market Revenue Growth Rate | Market Cap Weighted Average | 4.9% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (6 months ago) | See Below |
| Future Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2024-03-31 | 112 | 1 | ||
| 2023-03-31 | 107 | 1 | ||
| 2022-03-31 | 101 | 1 | ||
| 2021-03-31 | 94 | 1 | ||
| 2020-03-31 | 86 | 8 | 5 | 1 |
| 2019-03-31 | 78 | 5 | 2 | 1 |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-09-30 | 73 | 1 | 0 |
| 2018-06-30 | 72 | 2 | 1 |
| 2018-03-31 | 70 | 3 | 1 |
| 2017-12-31 | 69 | 5 | 0 |
| 2017-09-30 | 68 | 6 | 0 |
| 2017-06-30 | 65 | 5 | 0 |
| 2017-03-31 | 63 | 4 | 0 |
| 2016-12-31 | 62 | 2 | 0 |
| 2016-09-30 | 61 | 0 | 1 |
| 2016-06-30 | 60 | 0 | 1 |
| 2016-03-31 | 58 | 0 | 1 |
| 2015-12-31 | 57 | -1 | 2 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (6 months ago) | See Below |
| Future Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
All data from Generix Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2024-03-31 | ||||
| 2023-03-31 | ||||
| 2022-03-31 | ||||
| 2021-03-31 | ||||
| 2020-03-31 | 0.22 | 0.22 | 0.22 | 1.00 |
| 2019-03-31 | 0.10 | 0.10 | 0.10 | 1.00 |
| Date (Data in EUR Millions) | EPS * |
|---|---|
| 2018-09-30 | 0.02 |
| 2018-06-30 | 0.03 |
| 2018-03-31 | 0.03 |
| 2017-12-31 | 0.02 |
| 2017-09-30 | 0.01 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | -0.01 |
| 2016-12-31 | 0.02 |
| 2016-09-30 | 0.04 |
| 2016-06-30 | 0.05 |
| 2016-03-31 | 0.06 |
| 2015-12-31 | 0.09 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Generix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Generix's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Generix has a total score of 4/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
GENX Past Performance
How has Generix performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Generix's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
- Generix's 1-year earnings growth exceeds its 5-year average (383.5% vs -49.1%)
- Generix's earnings growth has exceeded the FR Software industry average in the past year (383.5% vs 17.4%).
Earnings and Revenue History
All data from Generix Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-09-30 | 73.27 | 0.50 | 4.69 | |
| 2018-06-30 | 71.78 | 0.53 | 4.69 | |
| 2018-03-31 | 70.29 | 0.57 | 4.69 | |
| 2017-12-31 | 69.01 | 0.33 | 4.38 | |
| 2017-09-30 | 67.72 | 0.10 | 4.08 | |
| 2017-06-30 | 65.36 | -0.04 | 4.08 | |
| 2017-03-31 | 63.00 | -0.18 | 4.08 | |
| 2016-12-31 | 61.87 | 0.35 | 3.76 | |
| 2016-09-30 | 60.73 | 0.87 | 3.44 | |
| 2016-06-30 | 59.56 | 1.06 | 3.44 | |
| 2016-03-31 | 58.39 | 1.24 | 3.44 | |
| 2015-12-31 | 57.20 | 1.92 | 3.49 | |
| 2015-09-30 | 56.01 | 2.60 | 3.54 | |
| 2015-06-30 | 54.84 | 2.25 | 3.54 | |
| 2015-03-31 | 53.67 | 1.91 | 3.54 | |
| 2014-12-31 | 51.92 | 2.61 | 3.29 | |
| 2014-09-30 | 50.17 | 3.31 | 3.05 | |
| 2014-06-30 | 49.78 | 3.75 | 3.05 | |
| 2014-03-31 | 49.40 | 4.18 | 3.05 | |
| 2013-09-30 | 42.31 | 1.98 | 2.93 | |
| 2013-06-30 | 45.33 | 0.92 | 2.93 | |
| 2013-03-31 | 48.34 | -0.14 | 2.93 | |
| 2012-12-31 | 63.38 | 1.13 | 3.38 | |
| 2012-09-30 | 63.62 | 0.64 | 3.19 | |
| 2012-06-30 | 63.94 | -0.74 | 3.19 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Generix has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Generix used its assets less efficiently than the FR Software industry average last year based on Return on Assets.
- Generix's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess Generix's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Software industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Generix has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
GENX Health
How is Generix's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Generix's finances.
The net worth of a company is the difference between its assets and liabilities.
- Generix's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Generix's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 2.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Generix Company Filings, last reported 6 months ago.
| Date (Data in EUR Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-09-30 | 39.04 | 18.97 | 5.70 |
| 2018-06-30 | 39.04 | 18.97 | 5.70 |
| 2018-03-31 | 37.48 | 13.96 | 6.78 |
| 2017-12-31 | 37.48 | 13.96 | 6.78 |
| 2017-09-30 | 39.80 | 16.51 | 5.24 |
| 2017-06-30 | 39.80 | 16.51 | 5.24 |
| 2017-03-31 | 39.23 | 13.16 | 6.94 |
| 2016-12-31 | 39.23 | 13.16 | 6.94 |
| 2016-09-30 | 36.14 | 18.24 | 7.34 |
| 2016-06-30 | 36.14 | 18.24 | 7.34 |
| 2016-03-31 | 35.98 | 7.86 | 5.46 |
| 2015-12-31 | 35.98 | 7.86 | 5.46 |
| 2015-09-30 | 35.60 | 10.36 | 3.06 |
| 2015-06-30 | 35.60 | 10.36 | 3.06 |
| 2015-03-31 | 34.71 | 7.26 | 7.99 |
| 2014-12-31 | 34.71 | 7.26 | 7.99 |
| 2014-09-30 | 41.08 | 4.17 | 9.40 |
| 2014-06-30 | 41.08 | 4.17 | 9.40 |
| 2014-03-31 | 42.21 | 6.13 | 4.77 |
| 2013-09-30 | 38.98 | 6.44 | 2.84 |
| 2013-06-30 | 38.98 | 6.44 | 2.84 |
| 2013-03-31 | 38.84 | 8.67 | 7.35 |
| 2012-12-31 | 38.84 | 8.67 | 7.35 |
| 2012-09-30 | 36.10 | 12.00 | 3.25 |
| 2012-06-30 | 36.10 | 12.00 | 3.25 |
- Generix's level of debt (48.6%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has increased over the past 5 years (16.5% vs 48.6% today).
- Debt is not well covered by operating cash flow (5.8%, less than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 12.4x coverage).
Financial health checks
We assess Generix's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Generix has a total score of 2/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
GENX Dividends
What is Generix's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
€2,000 of
Generix
shares you are expected to receive
€0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Generix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Generix's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
| France Software Industry Average Dividend Yield | Market Cap Weighted Average of 10 Stocks | 0.5% |
| France Market Average Dividend Yield | Market Cap Weighted Average of 324 Stocks | 2.9% |
| France Minimum Threshold Dividend Yield | 10th Percentile | 0.9% |
| France Bottom 25% Dividend Yield | 25th Percentile | 1.6% |
| France Top 25% Dividend Yield | 75th Percentile | 4.3% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in €) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2024-03-31 | ||
| 2023-03-31 | ||
| 2022-03-31 | ||
| 2021-03-31 | ||
| 2020-03-31 | ||
| 2019-03-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Generix has not reported any payouts.
- Unable to verify if Generix's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Generix's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Generix afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Generix has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
GENX Management
CEO
| TENURE AS CEO | 0.5 years |
CEO Bio
Aïda Collette-Sène has been Chief Executive Officer at Generix SA since October 2018.
CEO Compensation
- Insufficient data for Aïda to compare compensation growth.
- Insufficient data for Aïda to establish whether their remuneration is reasonable compared to companies of similar size in France.
Management Team
Jean-Charles Deconninck
Chairman of Management Board & President
€345K
0.5 yrs
Ludovic Luzza
Chief Financial & Administrative Officer and Member of Management Board
€152K
Philippe Seguin
Chief Operating Officer
€199K
Aïda Sène
Chief Executive Officer
0.5 yrs
Christophe Verdenne
Chief Sales Officer
Board of Directors Tenure
Average tenure of the Generix board of directors in years:
- The average tenure for the Generix board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors
François Poirier
Chairman of the Supervisory Board
€9K
56
7.6 yrs
Gérard Claverie
Vice Chairman of Supervisory Board
€9K
13.4 yrs
Jean-Philippe Gallant
Independent Member of the Supervisory Board
€9K
77
14.2 yrs
Jean-François Gautier
Independent Member of Supervisory Board
€9K
9.8 yrs
Dominique Despiney
Independent Member of the Supervisory Board
€9K
10.5 yrs
Roland Bonnet
Member of Supervisory Board
€9K
11.4 yrs
Marie-Laure Bordais
Member of Supervisory Board
€9K
7.6 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (€) | Value (€) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Generix's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Generix has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
GENX News
Simply Wall St News
Do Institutions Own Generix SA (EPA:GENX) Shares?
Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Generix is not a large company by global standards. … Our analysis of the ownership of the company, below, shows that.
Simply Wall St - – Full articleShould Generix Be Disappointed With Their 97% Profit?
To wit, the Generix share price has climbed 97% in five years, easily topping the market return of 29% (ignoring dividends). … One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). … During five years of share price growth, Generix actually saw its EPS drop 20% per year.
Simply Wall St - – Full articleShould You Be Concerned About Generix SA's (EPA:GENX) ROE?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … Our data shows Generix has a return on equity of 2.8% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleWhat Investors Should Know About Generix SA's (EPA:GENX) Financial Strength
Investors are always looking for growth in small-cap stocks like Generix SA (EPA:GENX), with a market cap of €71m. … However, an important fact which most ignore is: how financially healthy is the business? … Evaluating financial health as part of your investment thesis is
Simply Wall St - – Full articleWhat Percentage Of Generix SA (EPA:GENX) Shares Do Insiders Own?
Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … Taking a look at the our data on the ownership groups (below), it's seems that.
Simply Wall St - – Full articleWhat Should Investors Know About Generix SA's (EPA:GENX) Return On Capital?
This share represents a portion of capital used by the company to operate the business, and it is important the company is able to use the capital base efficiently to create adequate cash flows for you as an investor. … Thus, to understand how your money can grow by investing in Generix, you need to look at what the company returns to owners for the use of their capital, which can be done in many ways but today we will use return on capital employed (ROCE) … Calculating Return On Capital Employed for GENX
Simply Wall St - – Full articleA Closer Look At Generix SA's (EPA:GENX) Uninspiring ROE
With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Another way to think of that is that for every €1 worth of equity in the company, it was able to earn €0.032. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleWho Owns Generix SA (EPA:GENX)?
As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … With a market capitalization of €79.7m, Generix is a small cap stock, so it might not be well known by many institutional investors. … Let's take a closer look to see what the different types of shareholder can tell us about GENX
Simply Wall St - – Full articleShould You Be Happy With Generix SA's (EPA:GENX) Performance Lately?
Examining Generix SA's (EPA:GENX) past track record of performance is an insightful exercise for investors. … Today I will assess GENX's latest performance announced on 31 March 2018 and compare these figures to its longer term trend and industry movements. … How Did GENX's Recent Performance Stack Up Against Its Past
Simply Wall St - – Full articleIs It Time To Buy Generix SA (EPA:GENX)?
As a small cap stock, hardly covered by any analysts, there is generally more of an opportunity for mispricing as there is less activity to push the stock closer to fair value? … Is there still an opportunity here to buy. … Today I will analyse the most recent data on Generix’s outlook and valuation to see if the opportunity still exists
Simply Wall St - – Full articleGENX Company Info
Description
Generix SA develops SaaS solutions for supply chain ecosystems. The company's supply chain hub platform offers supply chain execution solutions, including warehouse management software; transport management software to reduce transport costs and associated administrative charges; manufacturing execution system that connects the warehouse to the production floor; enterprise asset management solution for inventory visibility in the field, spare parts management, and asset visibility and tracking; yard management software; and logistics order management system. Its supply chain hub platform also provides B2B integration solutions, such as EDI software, invoice services solution, finance and government services solution, and fax/PDF/OCR solution; and collaboration and visibility solutions comprising supplier, customer, carrier, 3PL, and invoice portals, as well as stock replenishment software, and order tracking and supply chain finance solutions. In addition, the company’s supply chain hub platform offers collaborative network; onboarding services, a solution that enables businesses to automate the process of enlisting B2B counterparts; and data lake, a key to analytics and predictive analytics. Further, it provides TradeXpress, a B2B integration software that supports various inter-application modes of mediation, such as EDI, B2B, MFT, ETL, EAI, and ESB, as well as management of regulated flows; and solutions for customer loyalty and interaction. The company operates in 50 countries worldwide. It primarily serves manufacturers, third-party logistics providers (3PL), and retailers. Generix SA was founded in 1990 and is headquartered in Lesquin, France.
Details
| Name: | Generix SA |
| GENX | |
| Exchange: | ENXTPA |
| Founded: | 1990 |
| €101,343,258 | |
| 22,127,349 | |
| Website: | http://www.generixgroup.com |
| Address: |
Generix SA ARTEPARC - Bât. A, 2 rue des Peupliers, Lesquin, Nord-Pas-de-Calais, 59810, France |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ENXTPA | GENX | Ordinary Shares | Euronext Paris | FR | EUR | 16. Jul 1998 | |
| LSE | 0JAW | Ordinary Shares | London Stock Exchange | GB | EUR | 16. Jul 1998 | |
| BATS-CHIXE | GENXP | Ordinary Shares | BATS 'Chi-X Europe' | GB | EUR | 16. Jul 1998 |
Number of employees
Current staff
Industry
| Application Software | |
| Software |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/24 21:27 |
| End of day share price update: | 2019/04/24 00:00 |
| Last estimates confirmation: | 2019/03/14 |
| Last earnings filing: | 2018/11/27 |
| Last earnings reported: | 2018/09/30 |
| Last annual earnings reported: | 2018/03/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
